The incidence, aetiology and treatment of fungal infections in a 60-bed department of clinical oncology over 2 years is reported. During the second year, after the moving of the department from an old to a new building with an improved epidemiologic regimen, the incidence decreased rapidly, although the mortality due to systemic disseminated mycosis did not change.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1439-0507.1992.tb00844.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Fungal Disease Response Centre: Pioneering Diagnostic Approach for Regions With Dispersed Hospital Centres.
Mycoses
January 2025
Laboratorio de Micología y Diagnóstico Molecular-Cátedra de Parasitología y Micología-Bioquímica, Universidad Nacional del Litoral, Santa Fe, Argentina.
Background: Access to fungal disease diagnosis is crucial for reducing mortality, yet it varies widely across Argentina, especially outside Buenos Aires. In regions like Santa Fe and Paraná, where most healthcare facilities are under 150 beds, maintaining specialised mycology labs is challenging.
Objectives: This work describes the establishment and first-year results of a centralised Fungal Disease Response Centre (FDRC) and referral network serving this region, covering approximately 1 million inhabitants.
Epidemiology of Coronavirus Disease 2019-Associated Fungal Infections in the Intensive Care Unit: A Single-Center Retrospective Study.
Mycopathologia
January 2025
Division of Infectious Diseases, University of Alabama, The University of Alabama at Birmingham, Birmingham, AL, USA.
Introduction: Invasive fungal disease (IFD) is a morbid superinfection that can arise in critically ill patients with COVID-19 infection. Studies evaluating the full spectrum of COVID-19-associated fungal infections remain limited.
Methods: Single-center retrospective study assessing IFD in patients with COVID-19, hospitalized for ≥ 72 h in the intensive care unit (ICU) between 02/25/20 and 02/28/22 (n = 1410).
Break through the mold: Hyper-IgE syndrome as a vehicle for invasive aspergillosis.
Respir Med Case Rep
December 2024
Division of Pulmonary and Critical Care Medicine, Department of Medicine, University of Nebraska Medical Center, Omaha, NE, USA.
Hyperimmunoglobulin E syndrome (HIGES) is a rare immunodeficiency characterized by high levels of immunoglobulin E (IgE) in the setting of various clinical features such as cutaneous candidiasis, asthma, recurrent rashes, and fungal infections. This case describes a 70-year-old male with cachexia and dyspnea found to have a cavitary lesion and aspergilloma, with remarkably high IgE and positive 1,3-β-D-glucan and Aspergillus testing. Herein, we describe the aforementioned case, review the available literature, and hypothesize the connection between invasive fungal infections and HIGES.
View Article and Find Full Text PDFFungal infection in patients treated with Bruton's Tyrosine Kinase inhibitor, from epidemiology to clinical outcome: A systematic review.
Clin Microbiol Infect
December 2024
Sorbonne Université, CIMI-Paris, AP-HP, Service de Parasitologie-Mycologie, Hopital de La Pitie-Salpetriere, F-75013 Paris, France. Electronic address:
Background: Bruton Tyrosine Kinase inhibitor (BTKi) emerged as key treatment for B-cell lymphomas. Despite its efficacy in the treatment of malignancies, numerous cases of invasive fungal infections (IFI) have been reported in patients receiving ibrutinib, a first generation BTKi. Cases of invasive aspergillosis have also been reported with acalabrutinib and zanubrutinib.
View Article and Find Full Text PDFEfficacy of two novel antifungal lipopeptides, AF and AF of bacillomycin D family in murine models of invasive candidiasis, cryptococcosis, and aspergillosis.
APMIS
January 2025
Department of Biological Sciences, BITS Pilani K.K. Birla Goa Campus, Zuari Nagar, Goa, India.
Invasive fungal diseases are an important public health concern due to an increase in the at-risk population and high mortality associated with these infections. Managing invasive fungal infections poses a significant challenge given the limited antifungal options and the emergence of resistance in key fungal pathogens. Through a comprehensive approach, we evaluated the in vitro antifungal activity and the in vivo efficacy of two novel lipopeptides, AF and AF in murine models of disseminated candidiasis, cryptococcosis, and aspergillosis.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!